Terms: = Lymphoma AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Diagnosis
14 results:
1. Golidocitinib, a selective jak1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Song Y; Malpica L; Cai Q; Zhao W; Zhou K; Wu J; Zhang H; Mehta-Shah N; Ding K; Liu Y; Li Z; Zhang L; Zheng M; Jin J; Yang H; Shuang Y; Yoon DH; Gao S; Li W; Zhai Z; Zou L; Xi Y; Koh Y; Li F; Prince M; Zhou H; Lin L; Liu H; Allen P; Roncolato F; Yang Z; Kim WS; Zhu J
Lancet Oncol; 2024 Jan; 25(1):117-125. PubMed ID: 38092009
[TBL] [Abstract] [Full Text] [Related]
2. Characteristics of Molecular Genetic Mutations and Their Correlation with Prognosis in Adolescent and Adult Patients with Acute Lymphoblastic Leukemia.
Sun X; Liu X; Li Y; Shi X; Li Y; Tan R; Jiang Y; Sui X; Ge X; Xu H; Wang X; Fang X
Oncology; 2024; 102(1):85-98. PubMed ID: 37437551
[TBL] [Abstract] [Full Text] [Related]
3. Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy.
Sharma M; Fu MP; Lu HY; Sharma AA; Modi BP; Michalski C; Lin S; Dalmann J; Salman A; Del Bel KL; Waqas M; Terry J; Setiadi A; Lavoie PM; Wasserman WW; Mwenifumbo J; Kobor MS; Lee AF; Kuchenbauer F; Lehman A; Cheng S; Cooper A; Patel MS; Turvey SE
Blood; 2022 Oct; 140(17):1858-1874. PubMed ID: 35789258
[TBL] [Abstract] [Full Text] [Related]
4. Cutaneous presentation of enteropathy-associated T-cell lymphoma masquerading as a DUSP22-rearranged CD30+ lymphoproliferation.
Bisig B; Cairoli A; Gaide O; Somja J; Bregnard C; Gaulard P; Xerri L; Lefort K; Missiaglia E; Gilliet M; Hohl D; Guenova E; de Leval L
Virchows Arch; 2022 Oct; 481(4):653-657. PubMed ID: 35366115
[TBL] [Abstract] [Full Text] [Related]
5. Refractory Celiac Disease.
Hujoel IA; Murray JA
Curr Gastroenterol Rep; 2020 Mar; 22(4):18. PubMed ID: 32185560
[TBL] [Abstract] [Full Text] [Related]
6. The IL-2RG R328X nonsense mutation allows partial STAT-5 phosphorylation and defines a critical region involved in the leaky-SCID phenotype.
Arcas-García A; Garcia-Prat M; Magallón-Lorenz M; Martín-Nalda A; Drechsel O; Ossowski S; Alonso L; Rivière JG; Soler-Palacín P; Colobran R; Sayós J; Martínez-Gallo M; Franco-Jarava C
Clin Exp Immunol; 2020 Apr; 200(1):61-72. PubMed ID: 31799703
[TBL] [Abstract] [Full Text] [Related]
7. [Study on Immunophenotypes and Gene of Acute Lymphoblastic Leukemia].
Zhao XF; Wang HY; Zhao X; Cheng HC; Li W; Liu SW; Qiu L; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):947-952. PubMed ID: 30111389
[TBL] [Abstract] [Full Text] [Related]
8. Aggressive B-cell lymphomas in patients with myelofibrosis receiving jak1/2 inhibitor therapy.
Porpaczy E; Tripolt S; Hoelbl-Kovacic A; Gisslinger B; Bago-Horvath Z; Casanova-Hevia E; Clappier E; Decker T; Fajmann S; Fux DA; Greiner G; Gueltekin S; Heller G; Herkner H; Hoermann G; Kiladjian JJ; Kolbe T; Kornauth C; Krauth MT; Kralovics R; Muellauer L; Mueller M; Prchal-Murphy M; Putz EM; Raffoux E; Schiefer AI; Schmetterer K; Schneckenleithner C; Simonitsch-Klupp I; Skrabs C; Sperr WR; Staber PB; Strobl B; Valent P; Jaeger U; Gisslinger H; Sexl V
Blood; 2018 Aug; 132(7):694-706. PubMed ID: 29907599
[TBL] [Abstract] [Full Text] [Related]
9. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish lymphoma Oncology Group.
Provencio M; Royuela A; Torrente M; Pollán M; Gómez-Codina J; Sabín P; Llanos M; Gumá J; Quero C; Blasco A; Aguiar D; García-Arroyo FR; Lavernia J; Martínez N; Morales M; Saenz-Cusi Á; Rodríguez D; Calvo V; de la Cruz-Merino L; de la Cruz MÁ; Rueda A;
Cancer; 2017 Oct; 123(19):3709-3716. PubMed ID: 28608996
[TBL] [Abstract] [Full Text] [Related]
11. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
[TBL] [Abstract] [Full Text] [Related]
12. Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms.
Pozdnyakova O; Hasserjian RP; Verstovsek S; Orazi A
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):253-61. PubMed ID: 25515354
[TBL] [Abstract] [Full Text] [Related]
13. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
Mullighan CG
Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
[TBL] [Abstract] [Full Text] [Related]
14. Somatically acquired jak1 mutations in adult acute lymphoblastic leukemia.
Flex E; Petrangeli V; Stella L; Chiaretti S; Hornakova T; Knoops L; Ariola C; Fodale V; Clappier E; Paoloni F; Martinelli S; Fragale A; Sanchez M; Tavolaro S; Messina M; Cazzaniga G; Camera A; Pizzolo G; Tornesello A; Vignetti M; Battistini A; Cavé H; Gelb BD; Renauld JC; Biondi A; Constantinescu SN; Foà R; Tartaglia M
J Exp Med; 2008 Apr; 205(4):751-8. PubMed ID: 18362173
[TBL] [Abstract] [Full Text] [Related]
